The DOI matches its Crossref record.
CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS
Abstract
The steady-state pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine (Sandimmune Neoral) were compared with the commercial formulation (Sandimmune) in 55 clinically stable renal allograft recipients. In study period I (2 weeks' duration), patients entered the study on a stable, individualized twice-daily dosage regimen of the commercial formulation. In period II (2 weeks), they were changed over to the microemulsion formulation at the same dose as at study entry. In period III (2 weeks), dose titration was subsequently allowed if necessary to provide comparable steady-state trough concentrations as at study entry. The commercial formulation was reinstituted during period IV (2 weeks). Safety and tolerability were assessed at weekly clinic visits, and the steady-state pharmacokinetics of cyclosporine in whole blood were characterized at the end of each study period. A milligram-to-milligram dose conversion was adequate when making the initial change between formulations in order to maintain steady-state trough concentrations in the target therapeutic range. Concomitant with this conversion, the steady-state peak concentration and area under the curve increased on average by 59% and 30%, respectively, due to absorption-related differences between the formulations. These increases were not associated with an increase in adverse experiences or changes in blood pressure or clinical laboratory parameters over the first four weeks after the change-over. Trough concentrations were more stable and were more strongly correlated with systemic exposure (area under the curve) during treatment with the microemulsion formulation. Intraindividual coefficients of variation in steady-state peak concentration, time to attain the peak, area under the curve, and percent peak-trough fluctuation ranged from 18% to 74% from the commercial formulation. Variability from the microemulsion formulation was significantly less, ranging from 10% to 22%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Margreiter, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07875-3 · Cited by 450
50 years of oral lipid-based formulations: provenance, progress and future perspectives
Feeney, O. M., Crum, M. F., McEvoy, C. L., Trevaskis, N. L., Williams, H. D., Pouton, C. W., Charman, W. N., Bergström, C. A. S., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.007 · Cited by 426
Phospholipids and Lipid-Based Formulations in Oral Drug Delivery
Fricker, G., Kromp, T., Wendel, A., Blume, A., Zirkel, J., Rebmann, H., Setzer, C., Quinkert, R.-O., Martin, F., & Müller-Goymann, C. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0130-x · Cited by 326
Malmsten, M. (2006) · Soft Matter · doi:10.1039/b608348j · Cited by 304
Metadata
- Authors
- KOVARIK, J. M., MUELLER, E. A., VAN BREE, J. B., FLÜCKIGER, S. S., LANGE, H., SCHMIDT, B., BOESKEN, W. H., LISON, A. E., & KUTZ, K.
- Venue
- Transplantation
- Published
- 1994-09
- Volume
- 58
- Issue
- 6
- Pages
- 663
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2036255046
- Cited by
- 242
- References
- 0
- FWCI
- 15.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS. https://app.cochat.ai/papers/10.1097/00007890-199409000-00004
- The paper
- KOVARIK, J. M., MUELLER, E. A., VAN BREE, J. B., FLÜCKIGER, S. S., LANGE, H., SCHMIDT, B., BOESKEN, W. H., LISON, A. E., & KUTZ, K. (1994). CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS. Transplantation. https://doi.org/10.1097/00007890-199409000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.